Moderna (MRNA)
(Delayed Data from NSDQ)
$57.46 USD
+0.15 (0.26%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $57.52 +0.06 (0.10%) 7:06 PM ET
4-Sell of 5 4
F Value B Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$57.46 USD
+0.15 (0.26%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $57.52 +0.06 (0.10%) 7:06 PM ET
4-Sell of 5 4
F Value B Growth D Momentum F VGM
Zacks News
Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed the most recent trading day at $159.87, moving -0.1% from the previous trading session.
Moderna (MRNA) Gives Pipeline Update, to Initiate New Pivotal Study
by Zacks Equity Research
Moderna (MRNA) is developing 14 mRNA-based vaccine candidates in different stages of clinical development. Interim data from ongoing cytomegalovirus and RSV vaccine studies are promising.
SMART Global, General Motors, Moderna, BioNTech and Johnson & Johnson highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
SMART Global, General Motors, Moderna, BioNTech and Johnson & Johnson highlighted as Zacks Bull and Bear of the Day
JNJ Vaccine Pause Gives Stay-at-Home ETFs a Shot in the Arm
by Sweta Killa
The U.S. regulators recommended an immediate pause on the use of Johnson & Johnson's (JNJ) COVID- 19 vaccine over reports of a "rare and severe type of blood clot" in six out of millions vaccinated.
Geron (GERN) Begins Phase III Myelofibrosis Study on Imetelstat
by Zacks Equity Research
Geron (GERN) is evaluating its lead pipeline candidate, imetelstat, in late-stage studies for refractory myelofibrosis and myelodysplastic syndromes.
Stock Market News for Apr 14, 2021
by Zacks Equity Research
The S&P 500 and the Nasdaq closed in the green on Tuesday backed by solid gains in tech stocks.
Which Vaccine Maker Will Win the Fight Against COVID-19?
by Kinjel Shah
A comparison between COVID-19 vaccines of Pfizer (PFE)/BioNTech (BNTX), Moderna's (MRNA), AstraZeneca (AZN) and J&J (JNJ) is inevitable.
J&J (JNJ) COVID-19 Jab to be Paused on FDA/CDC Recommendation
by Zacks Equity Research
FDA/CDC said that rare and severe blood clots accompanied by low levels of blood platelets have been identified in six individuals who received J&J's (JNJ) COVID-19 vaccine.
S&P 500 Hits Another New All-Time High
by Mark Vickery
The index's totals weren't super-noteworthy in the daily performance, +0.33%, but this April has seen multiple new highs four of the past six sessions.
Sage (SAGE), Biogen Report Positive Data on Essential Tremor Study
by Zacks Equity Research
Sage (SAGE) and partner Biogen (BIIB) announce positive top-line results from the phase II, placebo-controlled KINETIC study in patients with essential tremor.
Myovant (MYOV), Pfizer Start Dosing in Relugolix Combo Study
by Zacks Equity Research
Myovant (MYOV) and Pfizer (PFE) initiate dosing in the phase III SERENE study evaluating the contraceptive efficacy of the relugolix combination tablet.
Consumer Price Index Rise 0.6%
by Zacks Equity Research
Consumer Price Index Rise 0.6%
CPI +0.6%: Higher, but Not Scary; JNJ Vax on Hold?
by Mark Vickery
Headline CPI last month reached +0.6%, 10 basis points ahead of consensus, and the highest single-month tally since June of 2009.
Bristol Myers' (BMY) Opdivo Combo Encouraging in NSCLC study
by Zacks Equity Research
Bristol Myers Squibb (BMY) announces positive results from a late-stage study evaluating Opdivo plus chemotherapy for resectable NSCLC.
Has Moderna (MRNA) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (MRNA) Outperforming Other Medical Stocks This Year?
Stock Market News for Apr 12, 2021
by Zacks Equity Research
Benchmarks hit record levels on Friday, closing in the green for consecutive weeks as investors shrugged off inflation fears and focused on quarterly earnings season amid reopening optimism
J&J's (JNJ) COVID-19 Jab Under EU Review for Rare Blood Clots
by Zacks Equity Research
The European drug regulator's safety committee is conducting a review to asses a link between J&J's (JNJ) COVID-19 vaccine and rare blood clots.
Bristol Myers' (BMY) Opdivo Combo Positive in ESCC Study
by Zacks Equity Research
Bristol Myers (BMY) announces encouraging data from the late-stage study evaluating Opdivo plus chemotherapy and Opdivo plus Yervoy in ESCC study.
ImmunityBio (IBRX) Reports Positive COVID-19 Vaccine Data
by Zacks Equity Research
ImmunityBio (IBRX) reports positive initial data on its COVID-19 vaccine candidate in healthy phase I study participants.
Higher-Than-Expected PPI in March
by Zacks Equity Research
Higher-Than-Expected PPI in March.
Merck (MRK) Keytruda Meets Endpoint in Kidney Cancer Study
by Zacks Equity Research
Merck (MRK) is developing a Keytruda monotherapy regimen for adjuvant treatment of renal cell carcinoma patients.
PPI Doubles Month Over Month to 1.0%
by Mark Vickery
We haven't seen a higher headline PPI figure since the fallout of the pandemic era, now more than a year ago.
Lilly's (LLY) JAK Inhibitor Olumiant Fails COVID-19 Study
by Zacks Equity Research
Lilly (LLY) and Incyte's Olumiant (baricitinib) in combination standard of care fails in a late-stage study evaluating it in hospitalized COVID-19 patients.
Top COVID-19 Vaccine Stories of March Put Biotech ETFs in Focus
by Sweta Jaiswal, FRM
Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence with multiple mutants.
AstraZeneca (AZN) COVID-19 Jab May Have Link to Rare Blood Clots
by Zacks Equity Research
European regulators find a possible link between AstraZeneca's (AZN) COVID-19 vaccine and rare blood clot events.